{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T23:31:55Z","timestamp":1780097515669,"version":"3.54.0"},"reference-count":183,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Advances in Kidney Disease and Health"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1053\/j.akdh.2023.04.001","type":"journal-article","created":{"date-parts":[[2023,8,30]],"date-time":"2023-08-30T03:21:42Z","timestamp":1693365702000},"page":"315-335","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Nonalcoholic Fatty Liver Disease and Chronic Kidney Disease Cross Talk"],"prefix":"10.1053","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1687-1129","authenticated-orcid":false,"given":"Jacob","family":"Nysather","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9293-2811","authenticated-orcid":false,"given":"Eda","family":"Kaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8589-7280","authenticated-orcid":false,"given":"Paul","family":"Manka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9044-6054","authenticated-orcid":false,"given":"Prakash","family":"Gudsoorkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wing-Kin","family":"Syn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1053\/j.akdh.2023.04.001_bib1","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1053\/j.gastro.2012.04.001","article-title":"The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology","volume":"142","author":"Chalasani","year":"2012","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1053\/j.akdh.2023.04.001_bib2","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/hep.28431","article-title":"Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes","volume":"64","author":"Younossi","year":"2016","journal-title":"Hepatology"},{"issue":"6","key":"10.1053\/j.akdh.2023.04.001_bib3","doi-asserted-by":"crossref","first-page":"2672","DOI":"10.1002\/hep.30251","article-title":"Global Perspectives on nonalcoholic fatty liver disease and nonalcoholic steatohepatitis","volume":"69","author":"Younossi","year":"2019","journal-title":"Hepatology"},{"issue":"10","key":"10.1053\/j.akdh.2023.04.001_bib4","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1002\/ijc.25797","article-title":"Non-alcoholic fatty liver disease progresses to hepatocellular carcinoma in the absence of apparent cirrhosis","volume":"128","author":"Ertle","year":"2011","journal-title":"Int J Cancer"},{"issue":"4","key":"10.1053\/j.akdh.2023.04.001_bib5","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1038\/s41575-020-00381-6","article-title":"Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention","volume":"18","author":"Huang","year":"2021","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"2","key":"10.1053\/j.akdh.2023.04.001_bib6","doi-asserted-by":"crossref","first-page":"329","DOI":"10.14218\/JCTH.2021.00178","article-title":"Metabolic-associated fatty liver disease (MAFLD): a multi-systemic disease beyond the liver","volume":"10","author":"Kaya","year":"2022","journal-title":"J Clin Transl Hepatol"},{"issue":"1","key":"10.1053\/j.akdh.2023.04.001_bib7","article-title":"Nonalcoholic fatty liver disease accelerates kidney function decline in patients with chronic kidney disease: a cohort study","volume":"8","author":"Jang","year":"2018","journal-title":"Sci Rep"},{"issue":"6","key":"10.1053\/j.akdh.2023.04.001_bib8","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1111\/joim.12964","article-title":"Nonalcoholic fatty liver disease increases risk of incident advanced chronic kidney disease: a propensity-matched cohort study","volume":"286","author":"Park","year":"2019","journal-title":"J Intern Med"},{"issue":"8","key":"10.1053\/j.akdh.2023.04.001_bib9","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1177\/2050640620944098","article-title":"Non-alcoholic fatty liver disease increases the risk of incident chronic kidney disease","volume":"8","author":"Kaps","year":"2020","journal-title":"United European Gastroenterol J"},{"key":"10.1053\/j.akdh.2023.04.001_bib10","doi-asserted-by":"crossref","DOI":"10.1177\/20406223211048649","article-title":"The association between NAFLD and risk of chronic kidney disease: a cross-sectional study","volume":"12","author":"Cao","year":"2021","journal-title":"Ther Adv Chronic Dis"},{"issue":"4","key":"10.1053\/j.akdh.2023.04.001_bib11","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1053\/j.ajkd.2014.05.019","article-title":"CKD and nonalcoholic fatty liver disease","volume":"64","author":"Targher","year":"2014","journal-title":"Am J Kidney Dis"},{"issue":"4","key":"10.1053\/j.akdh.2023.04.001_bib12","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.diabet.2019.11.003","article-title":"Higher liver stiffness scores are associated with early kidney dysfunction in patients with histologically proven non-cirrhotic NAFLD","volume":"46","author":"Sun","year":"2020","journal-title":"Diabetes Metab"},{"issue":"5","key":"10.1053\/j.akdh.2023.04.001_bib13","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1038\/nrneph.2017.16","article-title":"Non-alcoholic fatty liver disease: an emerging driving force in chronic kidney disease","volume":"13","author":"Targher","year":"2017","journal-title":"Nat Rev Nephrol"},{"issue":"23","key":"10.1053\/j.akdh.2023.04.001_bib14","first-page":"1","article-title":"Liver transplantation in patients with non-alcoholic steatohepatitis and alcohol-related liver disease: the dust is yet to settle","volume":"7","author":"Satapathy","year":"2022","journal-title":"Transl Gastroenterol Hepatol"},{"issue":"18","key":"10.1053\/j.akdh.2023.04.001_bib15","first-page":"1","article-title":"Peri-transplant renal dysfunction in patients with non-alcoholic steatohepatitis undergoing liver transplantation","volume":"5","author":"Maiwall","year":"2020","journal-title":"Transl Gastroenterol Hepatol"},{"issue":"7","key":"10.1053\/j.akdh.2023.04.001_bib16","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.1681\/ASN.2005010106","article-title":"Metabolic syndrome and the risk for chronic kidney disease among nondiabetic adults","volume":"16","author":"Kurella","year":"2005","journal-title":"J Am Soc Nephrol"},{"issue":"12","key":"10.1053\/j.akdh.2023.04.001_bib17","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1038\/nrneph.2009.173","article-title":"Emerging risk factors and markers of chronic kidney disease progression","volume":"5","author":"Kronenberg","year":"2009","journal-title":"Nat Rev Nephrol"},{"issue":"1","key":"10.1053\/j.akdh.2023.04.001_bib18","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/nrgastro.2017.109","article-title":"Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention","volume":"15","author":"Younossi","year":"2018","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"3","key":"10.1053\/j.akdh.2023.04.001_bib19","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1007\/s00125-007-0897-4","article-title":"Non-alcoholic fatty liver disease is independently associated with an increased prevalence of chronic kidney disease and proliferative\/laser-treated retinopathy in type 2 diabetic patients","volume":"51","author":"Targher","year":"2008","journal-title":"Diabetologia"},{"issue":"7","key":"10.1053\/j.akdh.2023.04.001_bib20","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1007\/s00125-010-1720-1","article-title":"Non-alcoholic fatty liver disease is independently associated with an increased prevalence of chronic kidney disease and retinopathy in type 1 diabetic patients","volume":"53","author":"Targher","year":"2010","journal-title":"Diabetologia"},{"issue":"1","key":"10.1053\/j.akdh.2023.04.001_bib21","doi-asserted-by":"crossref","first-page":"92","DOI":"10.11613\/BM.2012.010","article-title":"Nonalcoholic fatty liver disease associated with impairment of kidney function in nondiabetes population","volume":"22","author":"Li","year":"2012","journal-title":"Biochem Med"},{"issue":"5","key":"10.1053\/j.akdh.2023.04.001_bib22","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1159\/000343885","article-title":"Association between nonalcoholic liver disease and chronic kidney disease: an ultrasound analysis from NHANES 1988-1994","volume":"36","author":"Sirota","year":"2012","journal-title":"Am J Nephrol"},{"issue":"2","key":"10.1053\/j.akdh.2023.04.001_bib23","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1111\/j.1478-3231.2011.02623.x","article-title":"Impaired renal function in morbid obese patients with nonalcoholic fatty liver disease","volume":"32","author":"Machado","year":"2012","journal-title":"Liver Int"},{"issue":"2","key":"10.1053\/j.akdh.2023.04.001_bib24","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1111\/liv.13992","article-title":"Chronic kidney disease is independently associated with increased mortality in patients with nonalcoholic fatty liver disease","volume":"39","author":"Paik","year":"2019","journal-title":"Liver Int"},{"issue":"7","key":"10.1053\/j.akdh.2023.04.001_bib36","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1001680","article-title":"Association of non-alcoholic fatty liver disease with chronic kidney disease: a systematic review and meta-analysis","volume":"11","author":"Musso","year":"2014","journal-title":"PLoS Med"},{"key":"10.1053\/j.akdh.2023.04.001_bib37","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.metabol.2017.11.003","article-title":"Nonalcoholic fatty liver disease increases risk of incident chronic kidney disease: a systematic review and meta-analysis","volume":"79","author":"Mantovani","year":"2018","journal-title":"Metabolism"},{"issue":"6","key":"10.1053\/j.akdh.2023.04.001_bib25","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1111\/j.1445-5994.2009.01979.x","article-title":"Impact of non-alcoholic fatty liver disease on microalbuminuria in patients with prediabetes and diabetes","volume":"40","author":"Hwang","year":"2010","journal-title":"Intern Med J"},{"issue":"1","key":"10.1053\/j.akdh.2023.04.001_bib26","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1373\/clinchem.2006.078980","article-title":"gamma-Glutamyltransferase as a predictor of chronic kidney disease in nonhypertensive and nondiabetic Korean men","volume":"53","author":"Ryu","year":"2007","journal-title":"Clin Chem"},{"issue":"4","key":"10.1053\/j.akdh.2023.04.001_bib27","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.metabol.2007.11.022","article-title":"Nonalcoholic fatty liver disease predicts chronic kidney disease in nonhypertensive and nondiabetic Korean men","volume":"57","author":"Chang","year":"2008","journal-title":"Metabolism"},{"issue":"10","key":"10.1053\/j.akdh.2023.04.001_bib28","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.2169\/internalmedicine.50.5043","article-title":"The development of chronic kidney disease in Japanese patients with non-alcoholic fatty liver disease","volume":"50","author":"Arase","year":"2011","journal-title":"Intern Med"},{"issue":"5","key":"10.1053\/j.akdh.2023.04.001_bib29","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/j.metabol.2010.07.022","article-title":"Nonalcoholic steatohepatitis and increased risk of chronic kidney disease","volume":"60","author":"Yasui","year":"2011","journal-title":"Metabolism"},{"issue":"6","key":"10.1053\/j.akdh.2023.04.001_bib30","doi-asserted-by":"crossref","first-page":"E606","DOI":"10.1111\/j.1399-0012.2011.01497.x","article-title":"Implications of worse renal dysfunction and medical comorbidities in patients with NASH undergoing liver transplant evaluation: impact on MELD and more","volume":"25","author":"Park","year":"2011","journal-title":"Clin Transplant"},{"issue":"3","key":"10.1053\/j.akdh.2023.04.001_bib31","doi-asserted-by":"crossref","first-page":"199","DOI":"10.4082\/kjfm.2013.34.3.199","article-title":"Non-alcoholic fatty liver disease and chronic kidney disease in Koreans aged 50 Years or Older","volume":"34","author":"Ahn","year":"2013","journal-title":"Korean J Fam Med"},{"issue":"2","key":"10.1053\/j.akdh.2023.04.001_bib32","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1111\/j.1464-5491.2011.03427.x","article-title":"Increased prevalence of chronic kidney disease in patients with Type 1 diabetes and non-alcoholic fatty liver","volume":"29","author":"Targher","year":"2012","journal-title":"Diabet Med"},{"issue":"6","key":"10.1053\/j.akdh.2023.04.001_bib33","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.2337\/dc13-2704","article-title":"Nonalcoholic fatty liver disease is independently associated with an increased incidence of chronic kidney disease in patients with type 1 diabetes","volume":"37","author":"Targher","year":"2014","journal-title":"Diabetes Care"},{"issue":"2","key":"10.1053\/j.akdh.2023.04.001_bib34","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s11255-016-1429-2","article-title":"Association between serum gamma-glutamyltransferase and chronic kidney disease in urban Han Chinese: a prospective cohort study","volume":"49","author":"Shen","year":"2017","journal-title":"Int Urol Nephrol"},{"issue":"3","key":"10.1053\/j.akdh.2023.04.001_bib35","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1080\/00365521.2019.1583366","article-title":"Non-invasive fibrosis scoring systems can predict future metabolic complications and overall mortality in non-alcoholic fatty liver disease (NAFLD)","volume":"54","author":"Onnerhag","year":"2019","journal-title":"Scand J Gastroenterol"},{"issue":"3","key":"10.1053\/j.akdh.2023.04.001_bib38","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1007\/s00125-021-05627-9","article-title":"Advanced liver fibrosis measured by transient elastography predicts chronic kidney disease development in individuals with non-alcoholic fatty liver disease","volume":"65","author":"Jung","year":"2022","journal-title":"Diabetologia"},{"issue":"12","key":"10.1053\/j.akdh.2023.04.001_bib39","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1111\/j.1751-7176.2011.00548.x","article-title":"Relationship between body mass index and high cystatin levels among US adults","volume":"13","author":"Shankar","year":"2011","journal-title":"J Clin Hypertens"},{"issue":"1","key":"10.1053\/j.akdh.2023.04.001_bib40","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1186\/s13643-019-1052-2","article-title":"Accurate GFR in obesity-protocol for a systematic review","volume":"8","author":"Sriperumbuduri","year":"2019","journal-title":"Syst Rev"},{"issue":"6","key":"10.1053\/j.akdh.2023.04.001_bib41","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/j.xkme.2020.08.008","article-title":"Performance of glomerular filtration rate estimating equations before and after bariatric surgery","volume":"2","author":"Chang","year":"2020","journal-title":"Kidney Med"},{"key":"10.1053\/j.akdh.2023.04.001_bib42","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.trsl.2016.12.004","article-title":"The metabolic syndrome and chronic kidney disease","volume":"183","author":"Zhang","year":"2017","journal-title":"Transl Res"},{"issue":"5","key":"10.1053\/j.akdh.2023.04.001_bib153","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.eprac.2022.03.010","volume":"28","author":"Cusi","year":"2022","journal-title":"Endocr Pract"},{"issue":"1","key":"10.1053\/j.akdh.2023.04.001_bib160","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/hep.29367","article-title":"The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases","volume":"67","author":"Chalasani","year":"2018","journal-title":"Hepatology"},{"issue":"1","key":"10.1053\/j.akdh.2023.04.001_bib161","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1111\/jgh.13857","article-title":"Asia-pacific Working party on non-alcoholic fatty liver disease guidelines 2017-Part 1: definition, risk factors and assessment","volume":"33","author":"Wong","year":"2018","journal-title":"J Gastroenterol Hepatol"},{"issue":"6","key":"10.1053\/j.akdh.2023.04.001_bib162","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/j.jhep.2015.11.004","article-title":"European association for the study of the L, European association for the study of D, European association for the study of O. EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease","volume":"64","year":"2016","journal-title":"J Hepatol"},{"issue":"3","key":"10.1053\/j.akdh.2023.04.001_bib163","doi-asserted-by":"crossref","first-page":"671","DOI":"10.3390\/cancers12030671","article-title":"Statin Use and the risk of hepatocellular carcinoma: a meta-analysis of observational studies","volume":"12","author":"Islam","year":"2020","journal-title":"Cancers"},{"issue":"3","key":"10.1053\/j.akdh.2023.04.001_bib164","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/j.jhep.2017.09.016","article-title":"Risk factors and prevention of hepatocellular carcinoma in the era of precision medicine","volume":"68","author":"Fujiwara","year":"2018","journal-title":"J Hepatol"},{"issue":"4","key":"10.1053\/j.akdh.2023.04.001_bib43","doi-asserted-by":"crossref","DOI":"10.1590\/1414-431x202010022","article-title":"Obesity as a predictive factor for chronic kidney disease in adults: systematic review and meta-analysis","volume":"54","author":"Pinto","year":"2021","journal-title":"Braz J Med Biol Res"},{"issue":"3","key":"10.1053\/j.akdh.2023.04.001_bib44","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1053\/j.ajkd.2018.02.362","article-title":"Obesity, metabolic Abnormality, and progression of CKD","volume":"72","author":"Yun","year":"2018","journal-title":"Am J Kidney Dis"},{"issue":"8","key":"10.1053\/j.akdh.2023.04.001_bib45","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1159\/000518111","article-title":"Metabolic syndrome, and not obesity, is associated with chronic kidney disease","volume":"52","author":"Ciardullo","year":"2021","journal-title":"Am J Nephrol"},{"issue":"4","key":"10.1053\/j.akdh.2023.04.001_bib46","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.diabet.2017.02.007","article-title":"Less liver fibrosis in metabolically healthy compared with metabolically unhealthy obese patients with non-alcoholic fatty liver disease","volume":"43","author":"Gutierrez-Grobe","year":"2017","journal-title":"Diabetes Metab"},{"issue":"11-12","key":"10.1053\/j.akdh.2023.04.001_bib47","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1111\/apt.15015","article-title":"The effects of metabolic status on non-alcoholic fatty liver disease-related outcomes, beyond the presence of obesity","volume":"48","author":"Ampuero","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"issue":"3","key":"10.1053\/j.akdh.2023.04.001_bib48","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1007\/BF03347427","article-title":"The correlation between adiposity and adiponectin, tumor necrosis factor alpha, interleukin-6 and high sensitivity C-reactive protein levels. Is adipocyte size associated with inflammation in adults?","volume":"30","author":"Bahceci","year":"2007","journal-title":"J Endocrinol Invest"},{"issue":"3","key":"10.1053\/j.akdh.2023.04.001_bib49","first-page":"682","article-title":"Impact of weight loss on markers of systemic inflammation in obese Saudi children with asthma","volume":"13","author":"Abd El-Kader","year":"2013","journal-title":"Afr Health Sci"},{"issue":"3","key":"10.1053\/j.akdh.2023.04.001_bib50","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1681\/ASN.2009080820","article-title":"Mechanisms linking obesity, chronic kidney disease, and fatty liver disease: the roles of fetuin-A, adiponectin, and AMPK","volume":"21","author":"Ix","year":"2010","journal-title":"J Am Soc Nephrol"},{"issue":"5","key":"10.1053\/j.akdh.2023.04.001_bib51","first-page":"1645","article-title":"Adiponectin regulates albuminuria and podocyte function in mice","volume":"118","author":"Sharma","year":"2008","journal-title":"J Clin Invest"},{"issue":"2","key":"10.1053\/j.akdh.2023.04.001_bib52","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.bbrc.2008.03.094","article-title":"Chronic activation of AMP-activated protein kinase-alpha1 in liver leads to decreased adiposity in mice","volume":"370","author":"Yang","year":"2008","journal-title":"Biochem Biophys Res Commun"},{"issue":"7348","key":"10.1053\/j.akdh.2023.04.001_bib53","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1038\/nature09968","article-title":"Aberrant lipid metabolism disrupts calcium homeostasis causing liver endoplasmic reticulum stress in obesity","volume":"473","author":"Fu","year":"2011","journal-title":"Nature"},{"issue":"4","key":"10.1053\/j.akdh.2023.04.001_bib54","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.cld.2009.07.003","article-title":"Apoptosis and cytokines in non-alcoholic steatohepatitis","volume":"13","author":"Syn","year":"2009","journal-title":"Clin Liver Dis"},{"issue":"7","key":"10.1053\/j.akdh.2023.04.001_bib55","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/nu11071664","article-title":"Lipotoxicity in kidney, heart, and skeletal muscle dysfunction","volume":"11","author":"Nishi","year":"2019","journal-title":"Nutrients"},{"issue":"9","key":"10.1053\/j.akdh.2023.04.001_bib56","doi-asserted-by":"crossref","first-page":"771","DOI":"10.5551\/jat.RV17023","article-title":"Pathophysiology of diabetic dyslipidemia","volume":"25","author":"Hirano","year":"2018","journal-title":"J Atheroscler Thromb"},{"issue":"5","key":"10.1053\/j.akdh.2023.04.001_bib57","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1136\/gutjnl-2020-322572","article-title":"Non-alcoholic fatty liver disease and risk of incident diabetes mellitus: an updated meta-analysis of 501 022 adult individuals","volume":"70","author":"Mantovani","year":"2021","journal-title":"Gut"},{"issue":"1","key":"10.1053\/j.akdh.2023.04.001_bib58","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/S2213-8587(20)30343-0","article-title":"Guideline recommendations and the positioning of newer drugs in type 2 diabetes care","volume":"9","author":"Marx","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"5","key":"10.1053\/j.akdh.2023.04.001_bib59","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1016\/j.jhep.2016.01.002","article-title":"Hepatic ceramides dissociate steatosis and insulin resistance in patients with non-alcoholic fatty liver disease","volume":"64","author":"Luukkonen","year":"2016","journal-title":"J Hepatol"},{"issue":"5","key":"10.1053\/j.akdh.2023.04.001_bib60","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1172\/JCI23621","article-title":"Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease","volume":"115","author":"Donnelly","year":"2005","journal-title":"J Clin Invest"},{"issue":"3","key":"10.1053\/j.akdh.2023.04.001_bib61","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1159\/000093632","article-title":"Insulin resistance, hyperinsulinemia, and renal injury: mechanisms and implications","volume":"26","author":"Sarafidis","year":"2006","journal-title":"Am J Nephrol"},{"issue":"6","key":"10.1053\/j.akdh.2023.04.001_bib62","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1152\/ajprenal.00340.2016","article-title":"Insulin resistance in chronic kidney disease: a systematic review","volume":"311","author":"Spoto","year":"2016","journal-title":"Am J Physiol Renal Physiol"},{"issue":"1","key":"10.1053\/j.akdh.2023.04.001_bib63","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1210\/er.2008-0033","article-title":"Hypothesis: could excessive fructose intake and uric acid cause type 2 diabetes?","volume":"30","author":"Johnson","year":"2009","journal-title":"Endocr Rev"},{"issue":"12","key":"10.1053\/j.akdh.2023.04.001_bib64","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1111\/nep.12343","article-title":"Associations of sugar-sweetened and artificially sweetened soda with chronic kidney disease: a systematic review and meta-analysis","volume":"19","author":"Cheungpasitporn","year":"2014","journal-title":"Nephrology"},{"issue":"6","key":"10.1053\/j.akdh.2023.04.001_bib65","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1002\/hep.23535","article-title":"Increased fructose consumption is associated with fibrosis severity in patients with nonalcoholic fatty liver disease","volume":"51","author":"Abdelmalek","year":"2010","journal-title":"Hepatology"},{"issue":"5","key":"10.1053\/j.akdh.2023.04.001_bib66","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1681\/ASN.2019101015","article-title":"Fructose production and metabolism in the kidney","volume":"31","author":"Nakagawa","year":"2020","journal-title":"J Am Soc Nephrol"},{"issue":"3","key":"10.1053\/j.akdh.2023.04.001_bib67","article-title":"Fructose and NAFLD: the multifaceted aspects of fructose metabolism","volume":"9","author":"Jegatheesan","year":"2017","journal-title":"Nutrients"},{"issue":"5","key":"10.1053\/j.akdh.2023.04.001_bib68","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1038\/nrgastro.2010.41","article-title":"The role of fructose in the pathogenesis of NAFLD and the metabolic syndrome","volume":"7","author":"Lim","year":"2010","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"7","key":"10.1053\/j.akdh.2023.04.001_bib69","doi-asserted-by":"crossref","first-page":"2632","DOI":"10.3390\/nu6072632","article-title":"Metabolic fate of fructose ingested with and without glucose in a mixed meal","volume":"6","author":"Theytaz","year":"2014","journal-title":"Nutrients"},{"issue":"48","key":"10.1053\/j.akdh.2023.04.001_bib70","doi-asserted-by":"crossref","first-page":"40732","DOI":"10.1074\/jbc.M112.399899","article-title":"Uric acid induces hepatic steatosis by generation of mitochondrial oxidative stress: potential role in fructose-dependent and -independent fatty liver","volume":"287","author":"Lanaspa","year":"2012","journal-title":"J Biol Chem"},{"key":"10.1053\/j.akdh.2023.04.001_bib71","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/1743-7075-10-32","article-title":"Fructose-induced stress signaling in the liver involves methylglyoxal","volume":"10","author":"Wei","year":"2013","journal-title":"Nutr Metab"},{"issue":"6","key":"10.1053\/j.akdh.2023.04.001_bib72","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.3904\/kjim.2020.410","article-title":"Renal effects of uric acid: hyperuricemia and hypouricemia","volume":"35","author":"Park","year":"2020","journal-title":"Korean J Intern Med"},{"issue":"2","key":"10.1053\/j.akdh.2023.04.001_bib73","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.cld.2022.01.008","article-title":"The Interplay between nonalcoholic fatty liver disease and kidney disease","volume":"26","author":"Truong","year":"2022","journal-title":"Clin Liver Dis"},{"key":"10.1053\/j.akdh.2023.04.001_bib74","doi-asserted-by":"crossref","DOI":"10.1155\/2021\/6889533","article-title":"The role and mechanism of oxidative stress and nuclear receptors in the development of NAFLD","volume":"2021","author":"Hong","year":"2021","journal-title":"Oxid Med Cell Longev"},{"issue":"8","key":"10.1053\/j.akdh.2023.04.001_bib75","doi-asserted-by":"crossref","first-page":"2116","DOI":"10.1093\/ndt\/gft103","article-title":"Chronic kidney disease is associated with increased platelet activation and poor response to antiplatelet therapy","volume":"28","author":"Gremmel","year":"2013","journal-title":"Nephrol Dial Transplant"},{"key":"10.1053\/j.akdh.2023.04.001_bib76","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.3389\/fphar.2018.01428","article-title":"The role of Nrf2 in liver disease: novel Molecular mechanisms and therapeutic Approaches","volume":"9","author":"Xu","year":"2018","journal-title":"Front Pharmacol"},{"issue":"3","key":"10.1053\/j.akdh.2023.04.001_bib77","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1007\/s11892-013-0372-1","article-title":"Nuclear factor (erythroid-derived 2)-like-2 factor (Nrf2), a key regulator of the antioxidant response to protect against atherosclerosis and nonalcoholic steatohepatitis","volume":"13","author":"Gupte","year":"2013","journal-title":"Curr Diab Rep"},{"issue":"4","key":"10.1053\/j.akdh.2023.04.001_bib78","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1056\/NEJMoa1105351","article-title":"Bardoxolone methyl and kidney function in CKD with type 2 diabetes","volume":"365","author":"Pergola","year":"2011","journal-title":"N Engl J Med"},{"issue":"43","key":"10.1053\/j.akdh.2023.04.001_bib79","doi-asserted-by":"crossref","first-page":"37085","DOI":"10.1074\/jbc.M111.290114","article-title":"Expression and characterization of a PNPLA3 protein isoform (I148M) associated with nonalcoholic fatty liver disease","volume":"286","author":"Huang","year":"2011","journal-title":"J Biol Chem"},{"issue":"1","key":"10.1053\/j.akdh.2023.04.001_bib80","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-018-21939-0","article-title":"Evaluation of polygenic determinants of non-alcoholic fatty liver disease (NAFLD) by a candidate genes resequencing strategy","volume":"8","author":"Di Costanzo","year":"2018","journal-title":"Sci Rep"},{"issue":"18","key":"10.1053\/j.akdh.2023.04.001_bib81","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/ijms20184444","article-title":"Nonalcoholic fatty liver disease (NAFLD), but not its susceptibility gene variants, Influences the decrease of kidney function in overweight\/obese children","volume":"20","author":"Di Costanzo","year":"2019","journal-title":"Int J Mol Sci"},{"issue":"8","key":"10.1053\/j.akdh.2023.04.001_bib82","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1053\/j.gastro.2016.01.037","article-title":"Genetic factors that affect risk of alcoholic and nonalcoholic fatty liver disease","volume":"150","author":"Anstee","year":"2016","journal-title":"Gastroenterology"},{"issue":"12","key":"10.1053\/j.akdh.2023.04.001_bib83","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1038\/ng.257","article-title":"Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease","volume":"40","author":"Romeo","year":"2008","journal-title":"Nat Genet"},{"issue":"3","key":"10.1053\/j.akdh.2023.04.001_bib84","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1002\/hep.28370","article-title":"The rs2294918 E434K variant modulates patatin-like phospholipase domain-containing 3 expression and liver damage","volume":"63","author":"Donati","year":"2016","journal-title":"Hepatology"},{"issue":"1","key":"10.1053\/j.akdh.2023.04.001_bib85","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1002\/hep.30625","article-title":"Relationship between PNPLA3 rs738409 polymorphism and decreased kidney function in children with NAFLD","volume":"70","author":"Targher","year":"2019","journal-title":"Hepatology"},{"issue":"10","key":"10.1053\/j.akdh.2023.04.001_bib86","doi-asserted-by":"crossref","DOI":"10.1111\/ijpo.12539","article-title":"Nonalcoholic fatty liver disease and eGFR levels could be linked by the PNPLA3 I148M polymorphism in children with obesity","volume":"14","author":"Marzuillo","year":"2019","journal-title":"Pediatr Obes"},{"key":"10.1053\/j.akdh.2023.04.001_bib87","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1053\/j.jrn.2022.01.007","article-title":"PNPLA3 I148M polymorphism Influences renal function in children with obesity and prediabetes","volume":"32","author":"Di Sessa","year":"2022","journal-title":"J Ren Nutr"},{"issue":"7","key":"10.1053\/j.akdh.2023.04.001_bib88","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0132640","article-title":"Influence of the PNPLA3 rs738409 polymorphism on non-alcoholic fatty liver disease and renal function among normal weight subjects","volume":"10","author":"Oniki","year":"2015","journal-title":"PLoS One"},{"issue":"2","key":"10.1053\/j.akdh.2023.04.001_bib89","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1002\/hep.27643","article-title":"PNPLA3 rs738409 and TM6SF2 rs58542926 gene variants affect renal disease and function in nonalcoholic fatty liver disease","volume":"62","author":"Musso","year":"2015","journal-title":"Hepatology"},{"issue":"5","key":"10.1053\/j.akdh.2023.04.001_bib90","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.diabet.2019.01.011","article-title":"Association between PNPLA3rs738409 polymorphism decreased kidney function in postmenopausal type 2 diabetic women with or without non-alcoholic fatty liver disease","volume":"45","author":"Mantovani","year":"2019","journal-title":"Diabetes Metab"},{"issue":"5","key":"10.1053\/j.akdh.2023.04.001_bib91","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1111\/liv.14419","article-title":"PNPLA3 I148M gene variant and chronic kidney disease in type 2 diabetic patients with NAFLD: clinical and experimental findings","volume":"40","author":"Mantovani","year":"2020","journal-title":"Liver Int"},{"issue":"1","key":"10.1053\/j.akdh.2023.04.001_bib92","doi-asserted-by":"crossref","first-page":"171","DOI":"10.3390\/ijms21010171","article-title":"FIB-4 index and diabetes mellitus are associated with chronic kidney disease in Japanese patients with non-alcoholic fatty liver disease","volume":"21","author":"Seko","year":"2019","journal-title":"Int J Mol Sci"},{"issue":"3","key":"10.1053\/j.akdh.2023.04.001_bib93","doi-asserted-by":"crossref","first-page":"720","DOI":"10.3390\/biomedicines10030720","article-title":"Metabolic syndrome but not fatty liver-associated genetic variants correlates with glomerular renal function decline in patients with non-alcoholic fatty liver disease","volume":"10","author":"Baratta","year":"2022","journal-title":"Biomedicines"},{"issue":"1","key":"10.1053\/j.akdh.2023.04.001_bib94","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1111\/liv.14251","article-title":"PNPLA3 rs738409 is associated with renal glomerular and tubular injury in NAFLD patients with persistently normal ALT levels","volume":"40","author":"Sun","year":"2020","journal-title":"Liver Int"},{"issue":"Suppl 1","key":"10.1053\/j.akdh.2023.04.001_bib95","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1159\/000447276","article-title":"Extrahepatic diseases and NAFLD: the Triangular relationship between NAFLD, type 2-diabetes and dysbiosis","volume":"34","author":"Scorletti","year":"2016","journal-title":"Dig Dis"},{"issue":"3","key":"10.1053\/j.akdh.2023.04.001_bib96","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1080\/17474124.2019.1569513","article-title":"Gut microbiota: novel therapeutic target for nonalcoholic fatty liver disease","volume":"13","author":"Suk","year":"2019","journal-title":"Expert Rev Gastroenterol Hepatol"},{"issue":"9","key":"10.1053\/j.akdh.2023.04.001_bib97","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1111\/apt.13376","article-title":"Systematic review: microbial dysbiosis and nonalcoholic fatty liver disease","volume":"42","author":"Wieland","year":"2015","journal-title":"Aliment Pharmacol Ther"},{"issue":"3","key":"10.1053\/j.akdh.2023.04.001_bib98","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1007\/s11154-014-9288-6","article-title":"Gut microbiota and GLP-1","volume":"15","author":"Everard","year":"2014","journal-title":"Rev Endocr Metab Disord"},{"key":"10.1053\/j.akdh.2023.04.001_bib99","doi-asserted-by":"crossref","first-page":"29","DOI":"10.3389\/fendo.2019.00029","article-title":"Impact of gut microbiota on Host Glycemic control","volume":"10","author":"Gerard","year":"2019","journal-title":"Front Endocrinol"},{"issue":"1","key":"10.1053\/j.akdh.2023.04.001_bib100","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1038\/s41598-017-01387-y","article-title":"Impaired renal function and dysbiosis of gut microbiota contribute to increased trimethylamine-N-oxide in chronic kidney disease patients","volume":"7","author":"Xu","year":"2017","journal-title":"Sci Rep"},{"issue":"5","key":"10.1053\/j.akdh.2023.04.001_bib101","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1038\/nm.3145","article-title":"Intestinal microbiota metabolism of L-carnitine, a nutrient in red meat, promotes atherosclerosis","volume":"19","author":"Koeth","year":"2013","journal-title":"Nat Med"},{"issue":"3","key":"10.1053\/j.akdh.2023.04.001_bib102","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1161\/CIRCRESAHA.116.305360","article-title":"Gut microbiota-dependent trimethylamine N-oxide (TMAO) pathway contributes to both development of renal insufficiency and mortality risk in chronic kidney disease","volume":"116","author":"Tang","year":"2015","journal-title":"Circ Res"},{"issue":"10215","key":"10.1053\/j.akdh.2023.04.001_bib103","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1016\/S0140-6736(19)33041-7","article-title":"Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial","volume":"394","author":"Younossi","year":"2019","journal-title":"Lancet"},{"issue":"7","key":"10.1053\/j.akdh.2023.04.001_bib104","doi-asserted-by":"crossref","first-page":"2974","DOI":"10.1210\/en.2011-2043","article-title":"Endoplasmic reticulum stress induces the expression of fetuin-A to develop insulin resistance","volume":"153","author":"Ou","year":"2012","journal-title":"Endocrinology"},{"issue":"3","key":"10.1053\/j.akdh.2023.04.001_bib105","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1530\/EJE-11-0864","article-title":"Fetuin A in nonalcoholic fatty liver disease: in\u00a0vivo and in\u00a0vitro studies","volume":"166","author":"Haukeland","year":"2012","journal-title":"Eur J Endocrinol"},{"issue":"8","key":"10.1053\/j.akdh.2023.04.001_bib106","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1038\/nm.2851","article-title":"Fetuin-A acts as an endogenous ligand of TLR4 to promote lipid-induced insulin resistance","volume":"18","author":"Pal","year":"2012","journal-title":"Nat Med"},{"issue":"8","key":"10.1053\/j.akdh.2023.04.001_bib107","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.tcm.2012.07.020","article-title":"Fetuin-A function in systemic mineral metabolism","volume":"22","author":"Herrmann","year":"2012","journal-title":"Trends Cardiovasc Med"},{"issue":"5","key":"10.1053\/j.akdh.2023.04.001_bib108","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1111\/j.1365-2265.2012.04460.x","article-title":"Plasma fetuin-A is associated with endothelial dysfunction and subclinical atherosclerosis in subjects with nonalcoholic fatty liver disease","volume":"78","author":"Dogru","year":"2013","journal-title":"Clin Endocrinol"},{"issue":"3","key":"10.1053\/j.akdh.2023.04.001_bib109","doi-asserted-by":"crossref","first-page":"c233","DOI":"10.1159\/000120209","article-title":"Serum fetuin-a concentration and endothelial dysfunction in chronic kidney disease","volume":"108","author":"Caglar","year":"2008","journal-title":"Nephron Clin Pract"},{"key":"10.1053\/j.akdh.2023.04.001_bib110","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/978-1-4614-0887-1_2","article-title":"Klotho and betaKlotho","volume":"728","author":"Kuro-o","year":"2012","journal-title":"Adv Exp Med Biol"},{"key":"10.1053\/j.akdh.2023.04.001_bib111","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2020.601349","article-title":"FGF19 and FGF21 for the treatment of NASH-Two Sides of the Same Coin? Differential and overlapping effects of FGF19 and FGF21 from mice to Human","volume":"11","author":"Henriksson","year":"2020","journal-title":"Front Endocrinol"},{"issue":"5","key":"10.1053\/j.akdh.2023.04.001_bib112","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1007\/s11684-019-0711-y","article-title":"The FGF metabolic axis","volume":"13","author":"Li","year":"2019","journal-title":"Front Med"},{"issue":"1","key":"10.1053\/j.akdh.2023.04.001_bib113","doi-asserted-by":"crossref","first-page":"74","DOI":"10.5527\/wjn.v4.i1.74","article-title":"ACE and ACE2 in kidney disease","volume":"4","author":"Mizuiri","year":"2015","journal-title":"World J Nephrol"},{"issue":"1-2","key":"10.1053\/j.akdh.2023.04.001_bib114","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.mce.2012.04.013","article-title":"The role of angiotensin II in nonalcoholic steatohepatitis","volume":"378","author":"Matthew Morris","year":"2013","journal-title":"Mol Cell Endocrinol"},{"issue":"4","key":"10.1053\/j.akdh.2023.04.001_bib115","doi-asserted-by":"crossref","first-page":"562","DOI":"10.3390\/ijms17040562","article-title":"NAFLD and chronic kidney disease","volume":"17","author":"Marcuccilli","year":"2016","journal-title":"Int J Mol Sci"},{"issue":"19","key":"10.1053\/j.akdh.2023.04.001_bib116","doi-asserted-by":"crossref","first-page":"3396","DOI":"10.3748\/wjg.v23.i19.3396","article-title":"Renin angiotensin system in liver diseases: Friend or foe?","volume":"23","author":"Simoes","year":"2017","journal-title":"World J Gastroenterol"},{"issue":"1","key":"10.1053\/j.akdh.2023.04.001_bib117","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1111\/liv.14272","article-title":"Pathways of hepatic and renal damage through non-classical activation of the renin-angiotensin system in chronic liver disease","volume":"40","author":"Sansoe","year":"2020","journal-title":"Liver Int"},{"issue":"1\u20133","key":"10.1053\/j.akdh.2023.04.001_bib118","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.regpep.2012.06.009","article-title":"Increased circulating angiotensin-(1-7) protects white adipose tissue against development of a proinflammatory state stimulated by a high-fat diet","volume":"178","author":"Santos","year":"2012","journal-title":"Regul Pept"},{"issue":"Suppl 4","key":"10.1053\/j.akdh.2023.04.001_bib119","doi-asserted-by":"crossref","first-page":"S58","DOI":"10.1038\/sj.ijo.0802858","article-title":"Ectopic fat storage in heart, blood vessels and kidneys in the pathogenesis of cardiovascular diseases","volume":"28","author":"Montani","year":"2004","journal-title":"Int J Obes Relat Metab Disord"},{"issue":"12","key":"10.1053\/j.akdh.2023.04.001_bib120","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1038\/nrneph.2009.184","article-title":"An update on the lipid nephrotoxicity hypothesis","volume":"5","author":"Ruan","year":"2009","journal-title":"Nat Rev Nephrol"},{"issue":"21","key":"10.1053\/j.akdh.2023.04.001_bib121","doi-asserted-by":"crossref","first-page":"18919","DOI":"10.1074\/jbc.M110650200","article-title":"Role of sterol regulatory element-binding protein 1 in regulation of renal lipid metabolism and glomerulosclerosis in diabetes mellitus","volume":"277","author":"Sun","year":"2002","journal-title":"J Biol Chem"},{"issue":"10","key":"10.1053\/j.akdh.2023.04.001_bib122","doi-asserted-by":"crossref","first-page":"3817","DOI":"10.1073\/pnas.1312436111","article-title":"Elevated hepatic 11beta-hydroxysteroid dehydrogenase type 1 induces insulin resistance in uremia","volume":"111","author":"Chapagain","year":"2014","journal-title":"Proc Natl Acad Sci USA"},{"issue":"5","key":"10.1053\/j.akdh.2023.04.001_bib123","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1161\/HYPERTENSIONAHA.111.175315","article-title":"Fatty kidney, hypertension, and chronic kidney disease: the Framingham Heart Study","volume":"58","author":"Foster","year":"2011","journal-title":"Hypertension"},{"issue":"6","key":"10.1053\/j.akdh.2023.04.001_bib124","doi-asserted-by":"crossref","DOI":"10.1111\/eci.13748","article-title":"Fatty kidney: a possible future for chronic kidney disease research","volume":"52","author":"Kanbay","year":"2022","journal-title":"Eur J Clin Invest"},{"key":"10.1053\/j.akdh.2023.04.001_bib125","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/978-981-19-0394-6_9","article-title":"Cholesterol metabolism in chronic kidney disease: Physiology, Pathologic mechanisms, and treatment","volume":"1372","author":"Pan","year":"2022","journal-title":"Adv Exp Med Biol"},{"issue":"3","key":"10.1053\/j.akdh.2023.04.001_bib126","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1093\/alcalc\/agz019","article-title":"Soluble alpha-klotho in liver cirrhosis and alcoholism","volume":"54","author":"Martin-Gonzalez","year":"2019","journal-title":"Alcohol Alcohol"},{"issue":"2","key":"10.1053\/j.akdh.2023.04.001_bib127","doi-asserted-by":"crossref","first-page":"183","DOI":"10.3350\/cmh.2021.0301","article-title":"Protective association of Klotho rs495392 gene polymorphism against hepatic steatosis in non-alcoholic fatty liver disease patients","volume":"28","author":"Liu","year":"2022","journal-title":"Clin Mol Hepatol"},{"issue":"1","key":"10.1053\/j.akdh.2023.04.001_bib128","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1159\/000452880","article-title":"Klotho\/FGF23 Axis in chronic kidney disease and cardiovascular disease","volume":"3","author":"Lu","year":"2017","journal-title":"Kidney Dis"},{"issue":"5","key":"10.1053\/j.akdh.2023.04.001_bib129","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1016\/j.kint.2016.05.019","article-title":"Fibroblast growth factor 23 directly targets hepatocytes to promote inflammation in chronic kidney disease","volume":"90","author":"Singh","year":"2016","journal-title":"Kidney Int"},{"issue":"4","key":"10.1053\/j.akdh.2023.04.001_bib130","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1681\/ASN.2013080905","article-title":"The gut microbiome, kidney disease, and targeted interventions","volume":"25","author":"Ramezani","year":"2014","journal-title":"J Am Soc Nephrol"},{"issue":"4","key":"10.1053\/j.akdh.2023.04.001_bib131","doi-asserted-by":"crossref","first-page":"252","DOI":"10.3390\/toxins13040252","article-title":"The impact of CKD on uremic toxins and gut microbiota","volume":"13","author":"Rysz","year":"2021","journal-title":"Toxins"},{"issue":"6","key":"10.1053\/j.akdh.2023.04.001_bib132","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1159\/000351171","article-title":"Oral activated charcoal adsorbent (AST-120) ameliorates chronic kidney disease-induced intestinal epithelial barrier disruption","volume":"37","author":"Vaziri","year":"2013","journal-title":"Am J Nephrol"},{"issue":"19","key":"10.1053\/j.akdh.2023.04.001_bib133","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.1182\/blood-2016-10-744060","article-title":"Indoxyl sulfate induces platelet hyperactivity and contributes to chronic kidney disease-associated thrombosis in mice","volume":"129","author":"Yang","year":"2017","journal-title":"Blood"},{"key":"10.1053\/j.akdh.2023.04.001_bib134","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.ypmed.2017.12.027","article-title":"The effect of multifactorial lifestyle interventions on cardiovascular risk factors: a systematic review and meta-analysis of trials conducted in the general population and high risk groups","volume":"109","author":"Sisti","year":"2018","journal-title":"Prev Med"},{"issue":"11","key":"10.1053\/j.akdh.2023.04.001_bib135","doi-asserted-by":"crossref","first-page":"2590","DOI":"10.1007\/s11695-016-2144-x","article-title":"Effects of bariatric surgery on mortality, cardiovascular events, and cancer outcomes in obese patients: systematic review and meta-analysis","volume":"26","author":"Zhou","year":"2016","journal-title":"Obes Surg"},{"issue":"9","key":"10.1053\/j.akdh.2023.04.001_bib136","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1001\/jamainternmed.2019.2248","article-title":"Association of weight loss interventions with changes in biomarkers of nonalcoholic fatty liver disease: a systematic review and meta-analysis","volume":"179","author":"Koutoukidis","year":"2019","journal-title":"JAMA Intern Med"},{"issue":"1","key":"10.1053\/j.akdh.2023.04.001_bib137","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1002\/hep.23276","article-title":"Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis","volume":"51","author":"Promrat","year":"2010","journal-title":"Hepatology"},{"issue":"3","key":"10.1053\/j.akdh.2023.04.001_bib138","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1136\/gut.2003.027581","article-title":"Modest weight loss and physical activity in overweight patients with chronic liver disease results in sustained improvements in alanine aminotransferase, fasting insulin, and quality of life","volume":"53","author":"Hickman","year":"2004","journal-title":"Gut"},{"issue":"18","key":"10.1053\/j.akdh.2023.04.001_bib139","doi-asserted-by":"crossref","first-page":"3390","DOI":"10.3390\/molecules24183390","article-title":"Trilobatin, a novel SGLT1\/2 inhibitor, Selectively induces the proliferation of Human Hepatoblastoma cells","volume":"24","author":"Wang","year":"2019","journal-title":"Molecules"},{"issue":"3","key":"10.1053\/j.akdh.2023.04.001_bib165","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1007\/s13300-021-01011-3","article-title":"Empagliflozin improves liver steatosis and fibrosis in patients with non-alcoholic fatty liver disease and type 2 diabetes: a randomized, double-blind, placebo-controlled clinical trial","volume":"12","author":"Chehrehgosha","year":"2021","journal-title":"Diabetes Ther"},{"issue":"1","key":"10.1053\/j.akdh.2023.04.001_bib166","doi-asserted-by":"crossref","DOI":"10.1186\/s12933-021-01237-2","article-title":"Effect of empagliflozin on ectopic fat stores and myocardial energetics in type 2 diabetes: the EMPACEF study","volume":"20","author":"Gaborit","year":"2021","journal-title":"Cardiovasc Diabetol"},{"issue":"1","key":"10.1053\/j.akdh.2023.04.001_bib167","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1002\/hep4.1696","article-title":"Ipragliflozin improves the hepatic outcomes of patients with diabetes with NAFLD","volume":"6","author":"Takahashi","year":"2022","journal-title":"Hepatol Commun"},{"issue":"1","key":"10.1053\/j.akdh.2023.04.001_bib168","doi-asserted-by":"crossref","DOI":"10.1136\/bmjdrc-2020-001990","article-title":"Comparing the effects of tofogliflozin and pioglitazone in non-alcoholic fatty liver disease patients with type 2 diabetes mellitus (ToPiND study): a randomized prospective open-label controlled trial","volume":"9","author":"Yoneda","year":"2021","journal-title":"BMJ Open Diabetes Res Care"},{"issue":"7","key":"10.1053\/j.akdh.2023.04.001_bib169","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1038\/s41591-022-01861-9","article-title":"Licogliflozin for nonalcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a study","volume":"28","author":"Harrison","year":"2022","journal-title":"Nat Med"},{"issue":"21","key":"10.1053\/j.akdh.2023.04.001_bib170","doi-asserted-by":"crossref","first-page":"3391","DOI":"10.2169\/internalmedicine.7134-21","article-title":"Effects of Canagliflozin on hepatic steatosis, visceral fat and skeletal muscle among patients with type 2 diabetes and non-alcoholic fatty liver disease","volume":"60","author":"Nishimiya","year":"2021","journal-title":"Intern Med"},{"key":"10.1053\/j.akdh.2023.04.001_bib171","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2021.613389","article-title":"Sodium-glucose cotransporter-2 inhibitors Ameliorate liver enzyme Abnormalities in Korean patients with type 2 diabetes mellitus and nonalcoholic fatty liver disease","volume":"12","author":"Euh","year":"2021","journal-title":"Front Endocrinol"},{"key":"10.1053\/j.akdh.2023.04.001_bib172","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/20420188211000243","article-title":"Effect of sodium-glucose cotransporter 2 inhibitor in patients with non-alcoholic fatty liver disease and type 2 diabetes mellitus: a propensity score-matched analysis of real-world data","volume":"12","author":"Arai","year":"2021","journal-title":"Ther Adv Endocrinol Metab"},{"issue":"2","key":"10.1053\/j.akdh.2023.04.001_bib173","doi-asserted-by":"crossref","first-page":"298","DOI":"10.2337\/dc19-0641","article-title":"Empagliflozin effectively lowers liver fat content in well-controlled type 2 diabetes: a randomized, double-blind, phase 4, placebo-controlled trial","volume":"43","author":"Kahl","year":"2020","journal-title":"Diabetes Care"},{"issue":"1","key":"10.1053\/j.akdh.2023.04.001_bib174","doi-asserted-by":"crossref","first-page":"259","DOI":"10.3390\/jcm9010259","article-title":"Ipragliflozin Additively ameliorates non-alcoholic fatty liver disease in patients with type 2 diabetes controlled with metformin and pioglitazone: a 24-Week randomized controlled trial","volume":"9","author":"Han","year":"2020","journal-title":"J Clin Med"},{"issue":"16","key":"10.1053\/j.akdh.2023.04.001_bib175","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.2169\/internalmedicine.4398-19","article-title":"SGLT2 inhibitor treatment outcome in nonalcoholic fatty liver disease complicated with diabetes mellitus: the long-term effects on clinical features and liver Histopathology","volume":"59","author":"Akuta","year":"2020","journal-title":"Intern Med"},{"issue":"2","key":"10.1053\/j.akdh.2023.04.001_bib176","doi-asserted-by":"crossref","first-page":"86","DOI":"10.3390\/diagnostics10020086","article-title":"Effect of sodium glucose cotransporter 2 inhibitors on renal function in patients with nonalcoholic fatty liver disease and type 2 diabetes in Japan","volume":"10","author":"Yano","year":"2020","journal-title":"Diagnostics"},{"key":"10.1053\/j.akdh.2023.04.001_bib177","doi-asserted-by":"crossref","first-page":"496453","DOI":"10.1100\/2012\/496453","article-title":"The effectiveness of liraglutide in nonalcoholic fatty liver disease patients with type 2 diabetes mellitus compared to sitagliptin and pioglitazone","volume":"2012","author":"Ohki","year":"2012","journal-title":"Sci World J"},{"issue":"11","key":"10.1053\/j.akdh.2023.04.001_bib178","doi-asserted-by":"crossref","first-page":"2434","DOI":"10.1007\/s00125-020-05265-7","article-title":"Effect of dulaglutide on liver fat in patients with type 2 diabetes and NAFLD: randomised controlled trial (D-LIFT trial)","volume":"63","author":"Kuchay","year":"2020","journal-title":"Diabetologia"},{"issue":"12","key":"10.1053\/j.akdh.2023.04.001_bib179","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1056\/NEJMoa2028395","article-title":"A placebo-controlled trial of Subcutaneous Semaglutide in nonalcoholic steatohepatitis","volume":"384","author":"Newsome","year":"2021","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1053\/j.akdh.2023.04.001_bib180","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s00125-019-05021-6","article-title":"Placebo-controlled randomised trial with liraglutide on magnetic resonance endpoints in individuals with type 2 diabetes: a pre-specified secondary study on ectopic fat accumulation","volume":"63","author":"Bizino","year":"2020","journal-title":"Diabetologia"},{"issue":"5","key":"10.1053\/j.akdh.2023.04.001_bib181","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1111\/liv.14065","article-title":"Randomized trial comparing effects of weight loss by liraglutide with lifestyle modification in non-alcoholic fatty liver disease","volume":"39","author":"Khoo","year":"2019","journal-title":"Liver Int"},{"issue":"10019","key":"10.1053\/j.akdh.2023.04.001_bib182","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/S0140-6736(15)00803-X","article-title":"Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study","volume":"387","author":"Armstrong","year":"2016","journal-title":"Lancet"},{"issue":"6","key":"10.1053\/j.akdh.2023.04.001_bib183","doi-asserted-by":"crossref","DOI":"10.1042\/BSR20181304","article-title":"Efficacy of liraglutide in treating type 2 diabetes mellitus complicated with non-alcoholic fatty liver disease","volume":"38","author":"Tian","year":"2018","journal-title":"Biosci Rep"},{"issue":"4","key":"10.1053\/j.akdh.2023.04.001_bib140","doi-asserted-by":"crossref","first-page":"F854","DOI":"10.1152\/ajprenal.00258.2017","article-title":"Renal hemodynamic effects of glucagon-like peptide-1 agonist are mediated by nitric oxide but not prostaglandin","volume":"313","author":"Thomson","year":"2017","journal-title":"Am J Physiol Renal Physiol"},{"issue":"1","key":"10.1053\/j.akdh.2023.04.001_bib141","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1210\/clinem\/dgab578","article-title":"The emerging role of glucagon-like peptide-1 receptor agonists for the management of NAFLD","volume":"107","author":"Patel Chavez","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"issue":"9491","key":"10.1053\/j.akdh.2023.04.001_bib142","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1016\/S0140-6736(05)67402-8","article-title":"The metabolic syndrome--a new worldwide definition","volume":"366","author":"Alberti","year":"2005","journal-title":"Lancet"},{"issue":"14","key":"10.1053\/j.akdh.2023.04.001_bib143","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1056\/NEJMra0912063","article-title":"Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease","volume":"363","author":"Targher","year":"2010","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1053\/j.akdh.2023.04.001_bib144","doi-asserted-by":"crossref","first-page":"57","DOI":"10.3892\/br.2012.18","article-title":"Metformin in non-alcoholic fatty liver disease: a systematic review and meta-analysis","volume":"1","author":"Li","year":"2013","journal-title":"Biomed Rep"},{"issue":"104799","key":"10.1053\/j.akdh.2023.04.001_bib145","first-page":"1","volume":"159","author":"Jalali","year":"2020","journal-title":"Pharmacol Res"},{"issue":"Suppl 2","key":"10.1053\/j.akdh.2023.04.001_bib146","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1002\/dmrr.249","article-title":"The mode of action of thiazolidinediones","volume":"18","author":"Hauner","year":"2002","journal-title":"Diabetes Metab Res Rev"},{"issue":"3","key":"10.1053\/j.akdh.2023.04.001_bib147","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1007\/s10238-016-0438-x","article-title":"Senescence in hepatic stellate cells as a mechanism of liver fibrosis reversal: a putative synergy between retinoic acid and PPAR-gamma signalings","volume":"17","author":"Panebianco","year":"2017","journal-title":"Clin Exp Med"},{"issue":"5","key":"10.1053\/j.akdh.2023.04.001_bib148","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.3892\/ijmm.2016.2766","article-title":"Rosuvastatin as a potential preventive drug for the development of hepatocellular carcinoma associated with non-alcoholic fatty liver disease in mice","volume":"38","author":"Yokohama","year":"2016","journal-title":"Int J Mol Med"},{"issue":"12","key":"10.1053\/j.akdh.2023.04.001_bib149","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1016\/j.metabol.2008.07.030","article-title":"Efficacy of atorvastatin for the treatment of nonalcoholic steatohepatitis with dyslipidemia","volume":"57","author":"Hyogo","year":"2008","journal-title":"Metabolism"},{"issue":"1","key":"10.1053\/j.akdh.2023.04.001_bib150","first-page":"39","article-title":"Therapeutic options in non-alcoholic steatohepatitis (NASH). Are all agents alike? Results of a preliminary study","volume":"16","author":"Georgescu","year":"2007","journal-title":"J Gastrointestin Liver Dis"},{"issue":"2","key":"10.1053\/j.akdh.2023.04.001_bib151","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1111\/jgh.15221","article-title":"Systematic review with meta-analysis: the effect of vitamin E supplementation in adult patients with non-alcoholic fatty liver disease","volume":"36","author":"Vadarlis","year":"2021","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1053\/j.akdh.2023.04.001_bib152","doi-asserted-by":"crossref","DOI":"10.1177\/1756284820974917","article-title":"The efficacy of vitamin E in reducing non-alcoholic fatty liver disease: a systematic review, meta-analysis, and meta-regression","volume":"13","author":"Abdel-Maboud","year":"2020","journal-title":"Therap Adv Gastroenterol"},{"issue":"4","key":"10.1053\/j.akdh.2023.04.001_bib154","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1016\/j.jhep.2011.08.018","article-title":"Omega-3 supplementation and non-alcoholic fatty liver disease: a systematic review and meta-analysis","volume":"56","author":"Parker","year":"2012","journal-title":"J Hepatol"},{"key":"10.1053\/j.akdh.2023.04.001_bib155","doi-asserted-by":"crossref","first-page":"1459790","DOI":"10.1155\/2016\/1459790","article-title":"Effects of omega-3 fatty acid in nonalcoholic fatty liver disease: a meta-analysis","volume":"2016","author":"Lu","year":"2016","journal-title":"Gastroenterol Res Pract"},{"issue":"5","key":"10.1053\/j.akdh.2023.04.001_bib156","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1161\/CIRCRESAHA.119.316337","article-title":"Nonalcoholic fatty liver disease Pandemic fuels the Upsurge in cardiovascular diseases","volume":"126","author":"Cai","year":"2020","journal-title":"Circ Res"},{"issue":"2","key":"10.1053\/j.akdh.2023.04.001_bib157","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.jchf.2018.10.007","article-title":"Heart failure and liver disease: Cardiohepatic Interactions","volume":"7","author":"Xanthopoulos","year":"2019","journal-title":"JACC Heart Fail"},{"issue":"1","key":"10.1053\/j.akdh.2023.04.001_bib158","doi-asserted-by":"crossref","first-page":"2884","DOI":"10.1038\/s41598-021-81959-1","article-title":"Clinical implications of renin-angiotensin system inhibitors for development and progression of non-alcoholic fatty liver disease","volume":"11","author":"Kim","year":"2021","journal-title":"Sci Rep"},{"issue":"2","key":"10.1053\/j.akdh.2023.04.001_bib159","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1002\/hep.32294","article-title":"Angiotensin-converting enzyme inhibitors prevent liver-related events in nonalcoholic fatty liver disease","volume":"76","author":"Zhang","year":"2022","journal-title":"Hepatology"}],"container-title":["Advances in Kidney Disease and Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2949813923000502?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2949813923000502?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T15:40:14Z","timestamp":1757432414000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2949813923000502"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":183,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["S2949813923000502"],"URL":"https:\/\/doi.org\/10.1053\/j.akdh.2023.04.001","relation":{},"ISSN":["2949-8139"],"issn-type":[{"value":"2949-8139","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Nonalcoholic Fatty Liver Disease and Chronic Kidney Disease Cross Talk","name":"articletitle","label":"Article Title"},{"value":"Advances in Kidney Disease and Health","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.akdh.2023.04.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 by the National Kidney Foundation, Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}